drugset / Trial / NCT04179734

Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder

NCT04179734

RandomizedCrossoverQuadruple-blindTreatment

Summary

A randomised, double-blind, placebo-controlled, two-way crossover physiological study. Designed to evaluate the effects of melanocortin-4 receptor (MC4R) activation on brain activity patterns and behavioural psychometric measures of sexual arousal during visual erotic stimuli in approximately 40 right-handed, heterosexual, premenopausal women aged 18 years and over with Hypoactive Sexual Desire Disorder (HSDD) for at least a 6 month duration.

Timeline

Start
2019-10-07
Primary completion
2020-10-06
Completion
2020-10-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bremelanotide Peptide 1.75 mg Subcutaneous